BIO vs RXRX · rev $2.58B vs rev $58.8M
BIO (BIO) versus Recursion Pharmaceuticals Inc (RXRX) — a side-by-side from cached financials, not a winner call.
BIO (BIO) common stock.
Recursion Pharmaceuticals Inc (RXRX) is a biotechnology company listed on NASDAQ.
Latest reported BIO revenue for 2025-12-31 was $2.58B. Net income was $759.9M. Revenue was up 0.7% from 2024-12-31 to 2025-12-31. BIO currently screens at market cap $0.
Latest reported RXRX revenue for 2024-12-31 was $58.8M. Net income was -$463.7M. Revenue was up 32.0% from 2023-12-31 to 2024-12-31. RXRX currently screens at market cap $1.75B.
BIO currently screens at market cap $0. RXRX currently screens at market cap $1.75B.
Not investment advice. Open the BIO and RXRX stock pages for the full models.
Not investment advice.